Zacks Small-Cap Research
Sponsored – Impartial - Comprehensive

May 19, 2025
David Bautz, PhD
312-265-9471
dbautz@zacks.com

scr.zacks.com
10 S. Riverside Plaza, Chicago, IL 60606

Cadrenal Therapeutics, Inc. (CVKD-NASDAQ)

CVKD: Preparations Continue for Phase 3 Trial of Tecarfarin…

Based on our probability adjusted DCF model that takes into account potential future revenues for tecarfarin in LVADs, ESKD+AFib, and mechanical heart valves, CVKD is valued at $30.00/share. This model is highly dependent upon continued clinical success of tecarfarin and will be adjusted accordingly based upon future clinical results.

Current Price (05/19/25)	$15.50
Valuation	**$30.00**

OUTLOOK

On May 8, 2025, Cadrenal Therapeutics, Inc. (CVKD) announced financial results for the first quarter of 2025 and provided a business update. The company has been laying the groundwork for a Phase 3 trial of tecarfarin in patients with left ventricular assist devices (LVAD). In support of this, Cadrenal recently announced a collaboration agreement with Abbott to support the planned TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices (TECH-LVAD) trial. Following a Type D meeting with the FDA in February 2025, the agency has requested that the company provide a full study design synopsis and detailed clinical trial design for review. Recently, Cadrenal completed the technical transfer and manufacturing of tecarfarin drug substance from a CDMO in Asia to one in the U.S. in support of the company's strategy and to improve supply chain security.

SUMMARY DATA

52-Week High	**$20.45**
52-Week Low	**$6.02**
One-Year Return (%)	**151.54**
Beta	**1.46**
Average Daily Volume (sh)	**24,869**
Shares Outstanding (mil)	**2**
Market Capitalization ($mil)	**$30**
Short Interest Ratio (days)	**N/A**
Institutional Ownership (%)	**8**
Insider Ownership (%)	**49**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**N/A**
Earnings Per Share (%)	**N/A**
Dividend (%)	**N/A**
P/E using TTM EPS	**N/A**
P/E using 2025 Estimate	**N/A**
P/E using 2026 Estimate	**N/A**

Risk Level	**Average**
Type of Stock	**Small-Growth**
Industry	**N/A**

ZACKS ESTIMATES

Revenue
(in millions of $)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2024	0.0 A	0.0 A	0.0 A	0.0 A	0.0 A
2025	0.0 A	0.0 E	0.0 E	0.0 E	0.0 E
2026					0.0 E
2027					0.0 E

Earnings per Share

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2024	-$1.56 A	-$2.24 A	-$2.18 A	-$2.55 A	-$8.73 A
2025	-$2.13 A	-$1.24 E	-$1.43 E	-$1.15 E	-$6.26 E
2026					-$2.20 E
2027					$1.57 E

WHAT'S NEW

Business Update

Gearing Up for Phase 3 Trial of Tecarfarin

Cadrenal Therapeutics, Inc. (CVKD) is a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant intended to prevent heart attacks, stroke, and death due to blood clots in patients suffering from rare cardiovascular conditions requiring chronic anticoagulation. These conditions include patients with left ventricular assist devices (LVADs), patients with end-stage kidney disease (ESKD) and atrial fibrillation (AFib), and patients with mechanical heart valves with difficult-to-control time in therapeutic range (TTR).

The company is currently preparing for the Phase 3 TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices (TECH-LVAD) trial. Recently, Cadrenal announced a collaboration agreement with Abbott in which Abbott will assist Cadrenal with trial design, site identification, trial awareness, and HeartMate 3™ expertise. Abbott is the maker of the HeartMate 3™ LVAD, which is the only LVAD currently approved in the U.S.

In February 2025, Cadrenal conducted a Type D meeting with the U.S. FDA at which time the agency provided additional guidance on the design of the planned Phase 3 trial. The FDA requested that Cadrenal provide a full study design synopsis and detailed clinical trial design for review. Tecarfarin was previously granted Orphan Drug Designation (ODD) by the FDA.

During the most recent quarter, Cadrenal completed the technical transfer and manufacturing of tecarfarin drug substance (API) from a Contract Development and Manufacturing Organization (CDMO) in Asia to a CDMO in the U.S. This was done in accordance with the company's strategy for tecarfarin and to improve supply chain security.

Currently, we anticipate initiation of the TECH-LVAD study in the second half of 2025.

Financial Update

On May 8, 2025, Cadrenal announced financial results for the first quarter of 2025. As expected, the company did not record any revenues for the three months ending March 31, 2025. R&D expenses in the first quarter of 2025 were $1.7 million compared to $0.6 million in the first quarter of 2024. The increase was primarily due to increased CMC costs, clinical trial preparation costs, stock-based compensation, and personnel-related expenses. G&A expenses were $2.3 million in the first quarter of 2025 compared to $1.1 million in the first quarter of 2024. The increase was primarily due to increased personnel-related expenses, public company expenses, and non-cash stock-based compensation

As of March 31, 2025, Cadrenal had approximately $7.3 million in cash and cash equivalents. Subsequent to the end of the quarter, the company sold 56,943 shares of common stock through its at-the-market (ATM) facility for net proceeds of approximately $876,000. While the company has sufficient capital to fund operations for the next 12 months, it will need to raise additional capital to conduct the planned Phase 3 tecarfarin trial. The company currently has approximately 2.0 million shares outstanding and, when factoring in stock options and warrants, a fully diluted share count of approximately 3.0 million.

Conclusion

We look forward to additional updates from the company regarding the upcoming Phase 3 trial of tecarfarin in LVAD patients. Having Abbott as a partner for the Phase 3 trial is a tremendous opportunity for the company as Abbott has extensive experience working with LVAD patients and conducting successful trials with that population. With no changes to our model our valuation remains at $30 per share.

PROJECTED FINANCIALS

Cadrenal Therapeutics, Inc.	2024 A	Q1 A	Q2 E	Q3 E	Q4 E	2025 E	2026 E	2027 E
Tecarfarin	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
License and other revenues	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Total Revenues	**$0.0**	**$0.0**	**$0.0**	**$0.0**	**$0.0**	**$0.0**	**$0.0**	**$0.0**
Cost of revenues	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Research & development	$4.2	$1.7	$1.1	$1.1	$1.2	$5.1	$6.0	$6.0
General & administrative	$6.8	$2.3	$1.2	$1.7	$1.2	$6.3	$5.0	$5.0
Depreciation Expense	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Operating Income	($11.0)	($3.9)	($2.3)	($2.8)	($2.4)	($11.4)	($11.0)	($11.0)
Non-Operating Expenses (Net)	($0.3)	($0.1)	($0.1)	($0.1)	($0.1)	($0.3)	$0.0	$0.0
Pre-Tax Income	($10.7)	($3.8)	($2.2)	($2.7)	($2.3)	($11.7)	($11.0)	($11.0)
Income Taxes	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0
Net Income	**($10.7)**	**($3.8)**	**($2.2)**	**($2.7)**	**($2.3)**	**($11.7)**	**($11.0)**	**($11.0)**
Net Margin	-	-	-	-	-	-	-	-
Reported EPS	**($8.73)**	**($2.13)**	**($1.24)**	**($1.43)**	**($1.15)**	**($6.26)**	**($2.20)**	**($1.57)**
YOY Growth	-	-	-	-	-	-	-	-
Basic Shares Outstanding	1.2	1.8	1.8	1.9	2.0	1.9	5.0	7.0

Source: Zacks Investment Research, Inc. *David Bautz, PhD*

HISTORICAL STOCK PRICE



DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, David Bautz, PhD, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.
Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business.
SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

CANADIAN COVERAGE

This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is resident outside of Canada, and is not an associated person of any Canadian registered adviser and/or dealer. Therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.